This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Pierre Fabre Medicament, Université Paris-Sud 11. Active years: 2012-2013.
Company Filing History:
2 out of 5,383 
2 out of 269 
2 out of 43 Years Active: 2012-2013
Title: Céline Mordant: Innovator in Anti-Cancer Therapy
Introduction
Céline Mordant is a notable inventor based in Saint Julien en Genevois, France. He has made significant contributions to the field of anti-cancer therapy through his innovative research and development of dimeric derivatives of artemisinin. With a total of two patents to his name, his work is recognized for its potential impact on cancer treatment.
Latest Patents
Céline Mordant's latest patents focus on dimeric derivatives of 10-trifluoromethylated artemisinin. The first patent describes the invention of these derivatives and their application in anti-cancer therapy. The invention relates to the preparation method of these derivatives and their uses, particularly in treating cancer. The second patent also addresses similar dimeric derivatives and their application in anticancer therapy, emphasizing their potential in the medical field.
Career Highlights
Throughout his career, Céline Mordant has worked with prominent organizations such as Pierre Fabre Medicament and the Centre National de La Recherche Scientifique. His experience in these institutions has contributed to his expertise in pharmaceutical research and development.
Collaborations
Céline has collaborated with esteemed colleagues, including Jean-Pierre Begue and Benoît Crousse. These partnerships have further enhanced his research efforts and innovation in the field.
Conclusion
Céline Mordant is a distinguished inventor whose work in developing dimeric derivatives of artemisinin holds promise for advancing anti-cancer therapies. His contributions to the field are significant and reflect his dedication to improving medical treatments.